- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Parareg has been withdrawn at the request of the marketing authorisation holder.
Product information
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Parareg
- Active substance
- cinacalcet
- International non-proprietary name (INN) or common name
- cinacalcet
- Therapeutic area (MeSH)
- Hypercalcemia
- Parathyroid Neoplasms
- Hyperparathyroidism
- Anatomical therapeutic chemical (ATC) code
- H05BX01
Pharmacotherapeutic group
Calcium homeostasisTherapeutic indication
Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.
Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).
Reduction of hypercalcaemia in patients with:
-parathyroid carcinoma.
- primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium
levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.